Synageva BioPharma Announces $80 Million Proposed Public Offering of Common Stock

  Synageva BioPharma Announces $80 Million Proposed Public Offering of Common
  Stock

Business Wire

LEXINGTON, Mass. -- January 3, 2013

Synageva BioPharma Corp.  (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare disorders,
today announced that it has commenced a $80 million underwritten public
offering of shares of its common stock. In connection with this offering,
Synageva expects to grant to the underwriters a 30-day option to purchase
additional shares of common stock, equal to up to 15% of the number of shares
of common stock sold in the offering. Morgan Stanley and J.P. Morgan are
acting as joint book-running managers in the offering, and Cowen and Company
is acting as co-manager in the offering.

The securities described above are being offered by Synageva pursuant to a
Form S-3 shelf registration statement (including a base prospectus) previously
filed with the Securities and Exchange Commission (“SEC”). Before you invest,
you should read the prospectus in the registration statement and related
prospectus supplement that Synageva has filed with the SEC for more complete
information about Synageva and this offering. The preliminary prospectus
supplement is available for free by visiting EDGAR on the SEC’s website
located at www.sec.gov. Copies of the preliminary prospectus supplement and
accompanying prospectus may also be obtained from the offices of Morgan
Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014,
Attn: Prospectus Department, by calling toll-free (866) 718 1649 or by email
at prospectus@morganstanley.com, or from the offices of J.P. Morgan Securities
LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717 or by calling toll-free (866) 803-9204.

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Synageva BioPharma Corp.

Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products for
patients with life-threatening rare diseases and unmet medical need. Synageva
has several protein therapeutics in its drug development pipeline. The company
has assembled a team with a proven record of bringing therapies to patients
with rare diseases.

Forward-Looking Statements

This news release contains “forward-looking statements” under the provisions
of the Private Securities Litigation Reform Act of 1995. Such statements can
be identified by introductory words such as “expects,” “plans,” “intends,”
“believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar
meaning and by the fact that they do not relate strictly to historical or
current facts. Many factors may cause actual results to differ materially from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known, including those
identified under the heading “Risk Factors” in the Company’s prospectus
supplement filed with the Securities and Exchange Commission (the “SEC”) on
January 3, 2013, and other filings Synageva periodically makes with the SEC
and others of which are not. Synageva cannot be sure when or if it will be
permitted by regulatory agencies to undertake additional clinical trials or to
commence any particular phase of clinical trials or how quickly patient
enrollment in clinical trials will occur. In addition, early clinical results
are not necessarily predictive of results that may be achieved from subsequent
clinical trials. Because of this, statements regarding the expected timing of
clinical trials or ultimate regulatory approval cannot be regarded as actual
predictions of when Synageva will obtain regulatory approval for any phase of
clinical trials or when it will obtain ultimate regulatory approval by a
particular regulatory agency or when any of its drug product candidates might
be commercialized. Synageva’s future financial results may differ from those
currently anticipated due to a number of factors, including unanticipated
costs in its research and development programs, fluctuations in royalty
revenues and unplanned costs associated with maintaining and enforcing patents
and other patent-related costs. No forward-looking statement is a guarantee of
future results or events, and investors should avoid placing undue reliance on
such statements. Synageva undertakes no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.

“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.

Contact:

Synageva
Matthew Osborne, 781-357-9947
matthew.osborne@synageva.com
 
Press spacebar to pause and continue. Press esc to stop.